Skip to main content
. 2024 Dec 1;13(12):1150. doi: 10.3390/antibiotics13121150

Table A5.

Characteristics of the patients according to mortality.

Mortality Value (Nr., %/Mean ± SD/Median (IQR)) p
Survivors (n = 65) Deceased (n = 4)
Age 59.12 ± 16.15 83 ± 6.58 0.001 *
Gender (male) 31 (47.7%) 0 (0%) 0.122 **
Septic shock 23 (35.4%) 4 (100%) 0.020 **
WBC 15.14 (13.19–18.21) 22.19 (18.27–24.5) 0.013 ***
CRP 112 (82–211.5) 226.5 (162.5–322) 0.057 ***
Procalcitonin 2.11 (0.75–4.9) 20.93 (5.08–39.67) 0.009 ***
ASA grading
I 2 (3.1%) 0 (0%) <0.001 **
II 37 (56.9%) 0 (0%)
III 13 (20%) 0 (0%)
IV 13 (20%) 1 (25%)
V 0 (0%) 3 (75%)
Comorbidities 26 (40%) 3 (75%) 0.302 **
Cardiovascular disease 26 (40%) 3 (75%) 0.302 **
Diabetes mellitus 2 (3.1%) 1 (25%) 0.166 **
Hinchey class
IIA 17 (26.2%) 0 (0%) 0.007 **
IIB 30 (46.2%) 0 (0%)
III 13 (20%) 2 (50%)
IV 5 (7.7%) 2 (50%)
Source control
Laparoscopic drainage 30 (46.2%) 0 (0%) 0.030 **
Laparoscopic resection + anastomosis 12 (18.5%) 0 (0%)
Laparoscopic Hartmann’s procedure 6 (9.2%) 0 (0%)
Open resection + anastomosis 3 (4.6%) 0 (0%)
Open Hartmann’s procedure 14 (21.5%) 4 (100%)
Multiple pathogens 10 (22.2%) 2 (66.7%) 0.150 **
ICU admission (days) 1 (1–2) 3.5 (2–8) 0.007 ***
Length of stay (days) 8 (6–10) 3.5 (2–8) 0.047 ***
Adequate empiric AB therapy 34 (75.6%) 2 (66.7%) 1.000 **

* Welch T-Test, ** Fisher’s Exact Test, *** Mann–Whitney U Test.